⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630408 | 1.00 | — | — | |
| SCHEMBL524142 | 1.00 | — | — | |
| SCHEMBL16429781 | 0.82 | — | — | |
| SCHEMBL523257 | 0.82 | — | — | |
| SCHEMBL3000480 | 0.82 | — | — | |
| SCHEMBL28929502 | 0.77 | — | — | |
| SCHEMBL524454 | 0.77 | — | — | |
| SCHEMBL6921399 | 0.77 | — | — | |
| SCHEMBL17342284 | 0.77 | — | — | |
| SCHEMBL9614688 | 0.77 | HLCS (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| CN-119855589-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-115348961-B | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024226892-A1 | HYDRAZONE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF | Verge Analytics, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4103559-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| CN-102822172-A | Substituted naphthyridines and their use as syk kinase inhibitors | BOEHRINGER INGELHEIM INT | 2012-12-12 | — | — | CN | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |